Johnson & Johnson Reports registry Data for Tirzepatide in Migraine

Johnson & Johnson today announced registry results for tirzepatide in patients with migraine. The study demonstrated that tirzepatide demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of migraine and support the continued development of tirzepatide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.